Daewon Pharmaceutical Co. Ltd. (003220) — Capital Reinvestment Ratio
Daewon Pharmaceutical Co. Ltd. (003220) has a Capital Reinvestment Ratio of 1.22x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩9.21 Billion) in capital expenditures (₩11.26 Billion). See how leveraged is Daewon Pharmaceutical Co. Ltd.'s balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daewon Pharmaceutical Co. Ltd. Capital Reinvestment Ratio (2011–2025)
This chart tracks Daewon Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 15 annual periods. Check 003220 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Daewon Pharmaceutical Co. Ltd. (2011–2025)
Year-by-year Capital Reinvestment Ratio for Daewon Pharmaceutical Co. Ltd. from 2011 to 2025. For the full cash flow conversion analysis, see 003220 operating cash flow.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.00x | ₩42.31 Billion | ₩42.13 Billion | ▼ -44.2% |
| 2024 | 1.78x | ₩30.04 Billion | ₩53.58 Billion | ▲ +347.8% |
| 2023 | 0.40x | ₩51.73 Billion | ₩20.61 Billion | ▼ -0.7% |
| 2022 | 0.40x | ₩33.33 Billion | ₩13.37 Billion | ▲ +119.0% |
| 2021 | 0.18x | ₩22.41 Billion | ₩4.10 Billion | ▼ -59.7% |
| 2020 | 0.45x | ₩24.95 Billion | ₩11.35 Billion | ▼ -57.4% |
| 2019 | 1.07x | ₩30.97 Billion | ₩33.03 Billion | ▲ +4.6% |
| 2018 | 1.02x | ₩40.03 Billion | ₩40.82 Billion | ▼ -70.4% |
| 2017 | 3.45x | ₩4.27 Billion | ₩14.71 Billion | ▲ +248.6% |
| 2016 | 0.99x | ₩20.79 Billion | ₩20.57 Billion | ▲ +29.0% |
| 2015 | 0.77x | ₩25.82 Billion | ₩19.80 Billion | ▼ -15.5% |
| 2014 | 0.91x | ₩17.45 Billion | ₩15.84 Billion | ▲ +13.6% |
| 2013 | 0.80x | ₩12.32 Billion | ₩9.85 Billion | ▲ +234.6% |
| 2012 | 0.24x | ₩13.83 Billion | ₩3.30 Billion | ▼ -58.0% |
| 2011 | 0.57x | ₩17.93 Billion | ₩10.19 Billion | — |